The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2025 | Venetoclax-based combinations with targeted agents for the treatment of AML
Musa Yilmaz, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, comments on the combination of venetoclax with targeted agents for the treatment of acute myeloid leukemia (AML). He discusses combinations involving IDH inhibitors, as well as menin inhibitors, that have shown encouraging responses. This interview took place at the 30th Congress of the European Hematology Association (EHA) in Milan, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
That’s an exciting field as it has been actually presented in this meeting in EHA 2025. There is HMA-Ven-IDH1 inhibitor combinations, IDH2 inhibitor combinations, and there are randomized studies that are planned to see whether or not patients benefit from these additions. But we know that from prospective single-arm studies that the patients are actually benefiting...
That’s an exciting field as it has been actually presented in this meeting in EHA 2025. There is HMA-Ven-IDH1 inhibitor combinations, IDH2 inhibitor combinations, and there are randomized studies that are planned to see whether or not patients benefit from these additions. But we know that from prospective single-arm studies that the patients are actually benefiting. It’s creating higher response rates, deeper remission and longer survival. Same with the menin inhibitor. We know that the menin inhibitor revumenib gained approval in the KMT2A-mutated patients and it improves response rates in these patients. Now we are combining not only that, but there are other menin inhibitors which are novel, which the results, at least the early results we are seeing is very encouraging and we’ll see how the field will evolve on these combinations.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
